liposomal doxorubicin + paclitaxel + topotecan

This is a **combination chemotherapy regimen** consisting of three separate cytotoxic drugs: **liposomal doxorubicin**, **paclitaxel**, and **topotecan**. Each component has a distinct mechanism of action and is used primarily as anti-cancer therapy. Liposomal doxorubicin is an anthracycline antibiotic formulated in liposomes to enhance delivery and reduce toxicity, paclitaxel is a microtubule-stabilizing agent, and topotecan is a topoisomerase I inhibitor. These drugs are all individually utilized as second-line or subsequent therapies in various solid tumors, most notably **ovarian cancer**, especially in cases resistant to platinum-based regimens. While clinical guidelines and evidence support the use of these agents individually or in pairs, there is insufficient evidence in the search results for the widespread use, approval, or pivotal clinical data specifically on the regimen combining all three drugs together as a fixed combination. Their mechanisms are complementary and may be considered in multi-agent chemotherapy for recurrent or refractory ovarian and gynecological cancers[2][4][5][7][8].